Ocular Therapeutix Ready for October Ophthalmology Engagements
Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical leader focused on transforming vision care through advanced therapies, is set to participate in a series of important meetings in Chicago this October. Their commitment to innovating solutions for retinal diseases and other eye conditions makes these events highly anticipated in the field of ophthalmology.
Insights into Presentation and Panel Schedules
This month, Ocular Therapeutix is involved in several panels and presentations across various ophthalmology conferences. Here’s what to expect:
Eyecelerator at AAO 2024
The Eyecelerator program is scheduled for October 17. The panel titled Fueling Progress: The Power of Innovation and Perseverance will feature Ocular's Executive Chair, Pravin U. Dugel, MD. This discussion is set to span from 10:00 AM to 11:00 AM, offering insights into the vital role of innovation in advancing retinal care.
Company Presentation on Transformation
Later that same day at the Eyecelerator Retina Showcase, Ocular Therapeutix will present Ocular Therapeutix: Transformation Into A Retina-focused Company. This session will be presented by Peter K. Kaiser, MD, the Chief Development Officer, scheduled for 1:24 PM to 1:31 PM, emphasizing the company's shift toward a strong focus on retinal treatments.
Participation in Innovate RETINA 2024
On October 17, Ocular Therapeutix will also participate in Innovate RETINA 2024, featuring a panel titled The Future of Retinal Therapeutics. Dr. Dugel will contribute to this forward-thinking discussion from 6:30 PM, highlighting emerging therapies and innovations that could reshape the landscape of retinal care.
Poster Presentations at AAO 2024
During the American Academy of Ophthalmology (AAO 2024) conference, running from October 18 to 21, Ocular Therapeutix will showcase a poster presentation. The presentation, Fifty-Two-Week Sustained Efficacy and Treatment Burden Reduction with OTX-TKI in the U.S. Phase 1 Trial for nAMD, led by David A. Eichenbaum, MD, FASRS, will be available on demand throughout the event, allowing attendees to delve into Ocular's latest research findings.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is dedicated to elevating vision care through its pioneering development of innovative therapies for a variety of retinal diseases and other ocular conditions. One of its primary product candidates, AXPAXLI™ (also known as OTX-TKI), employs a proprietary bioresorbable hydrogel-based formulation. Presently, AXPAXLI is undergoing Phase 3 clinical trials focusing on wet age-related macular degeneration (wet AMD), showcasing the company's commitment to advancing treatment options.
Diverse Pipeline of Innovative Therapies
Additionally, Ocular Therapeutix has leveraged its ELUTYX technology across various products, including DEXTENZA®, which has received FDA approval for treating ocular inflammation and pain after surgery. The company is also progressing with its trial for PAXTRAVA™, an intracameral implant targeting open-angle glaucoma, which has successfully completed Phase 2 clinical trials.
Stay Connected with Ocular Therapeutix
For the latest updates and information, stakeholders can follow Ocular Therapeutix through its official website, LinkedIn page, and X platform. With their ongoing efforts toward innovation in vision care, Ocular Therapeutix continues to lead in the development of effective treatments.
Frequently Asked Questions
What is Ocular Therapeutix known for?
Ocular Therapeutix specializes in innovative therapies aimed at treating retinal diseases and other ocular conditions.
When and where will Ocular Therapeutix be presenting?
The company will present at several key ophthalmology meetings in Chicago during October.
Who is presenting on behalf of Ocular Therapeutix?
Presentations will feature key executives including Pravin U. Dugel, MD and Peter K. Kaiser, MD.
What is the significance of the trials for AXPAXLI?
AXPAXLI is in Phase 3 trials, focusing on wet AMD, which represents a crucial step in advancing retinal therapy.
How can I keep up with Ocular Therapeutix news?
You can follow Ocular Therapeutix on their official website, LinkedIn, and X for updates and announcements.